Zhong Chuanhong, Tao Bei, Chen Yitian, Guo Zhangchao, Yang Xiaobo, Peng Lilei, Xia Xiangguo, Chen Ligang
Neurosurgery Department, Affiliated Hospital of Southwest Medical University, Luzhou, People's Republic of China.
Neurosurgical Clinical Medical Research Center of Sichuan Province, Luzhou, People's Republic of China.
Onco Targets Ther. 2020 Mar 12;13:2215-2224. doi: 10.2147/OTT.S237841. eCollection 2020.
The aim of this study was to explore the potential role of B7-H3 in malignant glioma progression and identify an innovative approach in clinical glioma therapy.
The protein expression of B7-H3 in high- and low-grade tumor tissues from glioma patients was assessed by immunohistochemistry. The proliferative and invasive ability of B7-H3-overexpressing or knockout glioma cells was analyzed in vitro and in vivo by CCK-8 assay and an orthotopic mouse glioma model, respectively. Activation of the JAK2/STAT3/Slug signaling pathway and epithelial-mesenchymal transition (EMT) was examined by Western blotting and immunofluorescence. The anticancer effects of napabucasin (NAP) and temozolomide (TMZ) were analyzed in an orthotopic mouse glioma model.
The expression of B7-H3 was higher in high-grade than in low-grade tumor tissues from glioma patients. In line with this, overexpression of B7-H3 enhanced glioma cell proliferation, induced sustained glioma growth, and promoted glioma cell invasion in vitro and in vivo. Moreover, these effects were mediated through the activation of the JAK2/STAT3/Slug signaling pathway in B7-H3 overexpression glioma cells. We also found that B7-H3 induced EMT processes through downregulation of E-cadherin and upregulation of MMP-2/-9 expression, resulting in enhanced invasion of glioma cells. Finally, we show that the combination of NAP and TMZ significantly suppressed glioma growth and glioma cell invasion, both in vitro and in vivo.
B7-H3 overexpression facilitated sustained glioma growth and promoted glioma cell invasion through a JAK2/STAT3/Slug-dependent signaling pathway. Application of the STAT3 inhibitor NAP significantly suppressed glioma growth and invasion, and has potential as a therapeutic strategy for the treatment of glioma.
本研究旨在探讨B7-H3在恶性胶质瘤进展中的潜在作用,并确定临床胶质瘤治疗的创新方法。
采用免疫组织化学法评估胶质瘤患者高、低级别肿瘤组织中B7-H3的蛋白表达。分别通过CCK-8法和原位小鼠胶质瘤模型在体外和体内分析过表达或敲除B7-H3的胶质瘤细胞的增殖和侵袭能力。通过蛋白质印迹法和免疫荧光法检测JAK2/STAT3/Slug信号通路的激活和上皮-间质转化(EMT)。在原位小鼠胶质瘤模型中分析萘布卡星(NAP)和替莫唑胺(TMZ)的抗癌作用。
胶质瘤患者高级别肿瘤组织中B7-H3的表达高于低级别肿瘤组织。与此一致的是,B7-H3的过表达增强了胶质瘤细胞的增殖,诱导了胶质瘤的持续生长,并促进了胶质瘤细胞在体外和体内的侵袭。此外,这些作用是通过B7-H3过表达的胶质瘤细胞中JAK2/STAT3/Slug信号通路的激活介导的。我们还发现,B7-H3通过下调E-钙黏蛋白和上调MMP-2/-9表达诱导EMT过程,导致胶质瘤细胞侵袭增强。最后,我们表明,NAP和TMZ联合使用在体外和体内均显著抑制了胶质瘤的生长和胶质瘤细胞的侵袭。
B7-H3的过表达通过JAK2/STAT3/Slug依赖性信号通路促进了胶质瘤的持续生长并促进了胶质瘤细胞的侵袭。STAT3抑制剂NAP的应用显著抑制了胶质瘤的生长和侵袭,具有作为胶质瘤治疗策略的潜力。